Indian API manufacturer Nectar Lifesciences late last month received an untitled letter from the FDA over repeat GMP violations, the FDA said, following a seven-day inspection at its Unit VI site in Himachal Pradesh, India, last March.
NEW YORK, Dec. 20, 2022 /PRNewswire/ -- Nectar, an innovative and comprehensive allergy care platform, announced today its $16.5 million Series A round led by Harmony Partners, with meaningful participation from founding partners Juxtapose and Obvious Ventures, who co-built the company with Founding CEO Kenneth Chahine, Ph.D.
Sixteen injured in blast at Indian manufacturer
Adynovate®. (Antihemophilic ): BAYER HEALTHCARE LLC v.NEKTAR THERAPEUTICS,nBAXALTA INCORPORATED, andnBAXALTA US INC
Repeated US FDA actions against leading Indian pharmaceutical companies, price control and adverse foreign exchange rates have started hitting their overall sales and bottom lines. The Pharmabiz study of 30 top Indian pharma companies in the first half of the current year clearly reflects adverse trend. The sales of these 30 companies account for almost 75 per cent of sales of Pharmabiz study of 100 companies during 2015-16.The growth in top line as well as bottom line of several companies remained single digit or negative during first half of 2016-17.
Nectar Lifesciences Ltd. bags ANVISA (Brazil) cGMP for Cephalosporin API’s manufacturing facility